- 1 Title: Plasmodium falciparum with pfhrp2/3 deletion not detected in a 2018-2021 malaria longitudinal
- 2 cohort study in Kinshasa Province, Democratic Republic of the Congo
- 3 Running head for use as a header (max 60 characters, including spaces): Pfhrp2/3 deletions in a malaria
- 4 longitudinal study in DRC

5

18

19

- 6 **Authors:** Ruthly François<sup>1</sup>, Melchior Mwandagalirwa Kashamuka<sup>2</sup>, Kristin Banek<sup>1</sup>, Joseph A. Bala<sup>2</sup>,
- 7 Marthe Nkalani<sup>2</sup>, Georges Kihuma<sup>2</sup>, Joseph Atibu<sup>2</sup>, Georges E. Mahilu<sup>2</sup>, Kyaw L. Thwai<sup>1</sup>, Ashenafi Assefa<sup>1</sup>,
- 8 Jeffrey A. Bailey<sup>3</sup>, Rhoel R. Dinglasan<sup>4</sup>, Jonathan J. Juliano<sup>1</sup>, Antoinette Tshefu<sup>2#</sup>, Jonathan B. Parr<sup>1#\*</sup>
- 9 Affiliations: <sup>1</sup>University of North Carolina at Chapel Hill, Chapel Hill, NC, United States, <sup>2</sup>Kinshasa School
- of Public Health, Kinshasa, Democratic Republic of the Congo, <sup>3</sup>Brown University, Providence, RI, United
- 11 States, <sup>4</sup> University of Florida, Gainesville, FL, United States.
- 12 #Co-senior authors
- 13 \* Corresponding: Jonathan B. Parr, MD, MPH; 111 Mason Farm Rd, CB#7036, Chapel Hill, NC 27599;
- 14 jonathan parr@med.unc.edu; 1-919-445-1132.
- 15 **Keywords:** Malaria, *Plasmodium falciparum*, hrp2, hrp3, Kinshasa
- 16 **Word count:** 136 (abstract); 1,004 (body)
- 17 **Number of figures and tables:** 3 (2 figures, 1 table)

## **Abstract**

Histidine-rich protein 2- (HRP2-) based rapid diagnostic tests (RDTs) are widely used to detect *Plasmodium falciparum* in sub-Saharan Africa. Reports of parasites with *pfhrp2* and/or *pfhrp3* (*pfhrp2/3*) gene deletions in Africa raise concerns about the long-term viability of HRP2-based RDTs. We evaluated changes in *pfhrp2/3* deletion prevalence over time using a 2018-2021 longitudinal study of 1,635 enrolled individuals in Kinshasa Province, Democratic Republic of the Congo (DRC). Samples collected during biannual household visits with  $\geq$  100 parasites/ $\mu$ L by quantitative real-time PCR were genotyped using a multiplex real-time PCR assay. Among 2,726 *P. falciparum* PCR-positive samples collected from 993 participants during the study period, 1,267 (46.5%) were genotyped. No *pfhrp2/3* deletions or mixed *pfhrp2/3*-intact and -deleted infections were identified in our study. *Pfhrp2/3*-deleted parasites were not detected in Kinshasa Province; ongoing use of HRP2-based RDTs is appropriate.

## Body

Progress toward malaria control and elimination in Africa requires prompt diagnosis and treatment with effective antimalarial drugs. Rapid diagnostic tests (RDTs) are widely used to identify individuals infected with *Plasmodium*; their deployment enabled significant improvements in malaria diagnostic testing across the continent over the past 15 years. The majority of RDTs used to diagnose falciparum malaria in sub-Saharan Africa detect *P. falciparum* histidine-rich protein 2 (HRP2) and its paralog HRP3, encoded by the *pfhrp2* and *pfhrp3* genes, respectively. HRP2-based RDTs are generally more sensitive and heat-stable than RDTs detecting other antigens. However, test-and-treat strategies that rely upon HRP2-based RDTs are threatened by the emergence of *P. falciparum* strains that escape detection due to deletion of the *pfhrp2* and/or *pfhrp3* (*pfhrp2/3*) genes. High prevalence of *pfhrp2/3*-deleted parasites in Eritrea, Ethiopia, 5,6 Djibouti, 7,8 and surrounding countries recently prompted

changes in malaria diagnostic testing policies. Reports from sub-Saharan countries outside of the Horn of Africa, however, indicate lower prevalence.<sup>9</sup>

The Democratic Republic of the Congo (DRC) has one of the highest malaria burdens in the world, accounting for 12% of global malaria cases and deaths. In the DRC, we previously reported 6.4% *pfhrp2* deletion prevalence in samples from a 2013-2014 nationally representative cross-sectional survey of asymptomatic children under five years of age. However, no *pfhrp2/3* deletions were observed in our 2017 cross-sectional study of symptomatic children and adults across three DRC provinces. These studies were both cross-sectional and did not provide information about how the prevalence of deletions may be changing over time. This study aims to estimate the *pfhrp2/3* deletion prevalence and changes over time in Kinshasa Province, DRC.

This study includes samples collected as part of a 2018-2021 longitudinal study of malaria conducted at seven sites across Kinshasa Province, DRC. A total of 1,635 participants were enrolled in one urban neighborhood, three peri-urban villages, and three rural villages (Figure 1). Study visits were conducted as part of twice-yearly household surveys in the dry and rainy seasons (active surveillance) and as part of routine care at local health centers (passive surveillance) as previously described. At each visit, a comprehensive questionnaire on malaria symptoms and treatment, and bed net usage was administered. A finger- or heel-prick sample was obtained at each visit for RDT (SD Bioline Ag P.f./Pan RDT [05FK60], Alere, Gyeonggi-do, Republic of Korea, or CareStart, Access Bio, Somerset, U.S.A.) and dried blood spot (DBS) preparation for future molecular investigation. RDT-positive patients were treated according to national guidelines.

DNA was extracted from DBS using Chelex-100 and saponin or tween as previously described.

14,15 Quantitative real-time PCR (qPCR) targeting the *P. falciparum lactate dehydrogenase* (*pfldh*) gene was used to estimate *P. falciparum* parasitemia, using serial dilutions of DNA extracted from a mock DBS

made with cultured P. falciparum 3D7 or FCR3 strain parasites at known parasite density. Samples with  $\geq$  100 parasites/ $\mu$ L were selected for pfhrp2/3 deletion identification using a multiplex real-time PCR assay that detects pfldh, pfhrp2, pfhrp3, and human beta-tubulin (HumTuBB). We used this parasite density threshold to reduce the risk of unintentional misclassification of deletions in the setting of low DNA concentrations. Positive calls required cycle threshold ( $C_t$ ) values < 35. Samples positive for HumTuBB and pfldh but negative for pfhrp2 or pfhrp3 were subjected to a confirmatory real-time PCR targeting the P. falciparum beta-tubulin (PfBtubulin) gene. Deletion calls were limited to samples positive for HumTuBB and both single-copy P. falciparum genes (pfldh and pftubulin), but negative for pfhrp2 and/or pfhrp3. Mixed infections of pfhrp2/3-intact and -deleted strains were defined conservatively as samples in which (pfhrp2  $C_t$  - pfldh  $C_t$ ) >3 or (pfhrp3  $C_t$  - pfldh  $C_t$ ) >3. All assays included P. pflciparum 3D7, DD2, and HB3 strain DNA as wildtype, pfhrp2-deleted, and pfhrp3-deleted controls, respectively. All participants provided informed consent. Ethical approval for this study was granted by the Institutional Review Boards of the University of North Carolina-Chapel Hill and the Kinshasa School of Public Health.

A total of 1,267 samples collected from 649 individuals in 179 households between 2018 and 2021 were included in this study (**Figure 2**). Among these, the median number of *P. falciparum* infections with  $\geq$  100 parasites/ $\mu$ L detected per participant was 2.0 (IQR: 1-3). The median age at enrollment in 2018 was 9 years old (IQR: 5-15 years old); 48.8% reported female gender. At the time of enrollment, 48.7% reported malaria in the preceding 6 months, and 42.7% of those reported more than one episode in that 6-month period. The median household size was 8 (IQR: 6-10), with high bed net coverage across the study population (90.2%). The baseline characteristics of the study population are summarized in **Table 1**.

All 1,267 samples had detectable human DNA as indicated by amplification of *HumTuBB with* C<sub>t</sub> < 35. The multiplex PCR confirmed *P. falciparum* parasitemia in all but 2 samples which failed to amplify

pfldh. Both pfhrp2 and pfhrp3 were negative in one sample ( $C_t > 35$  for both gene targets). However, pfldh was negative in the multiplex assay and Pftubulin negative in follow-up testing, indicating that the original pfldh qPCR result was a false-positive. Thus, this sample did not meet criteria to be considered a pfhrp2/3-deleted parasite. There were no mixed infections of pfhrp2/3-intact and -deleted strains identified in our study population.

Overall, we did not find evidence of *pfhrp2/3* deletion in parasites sampled during our longitudinal cohort in Kinshasa Province. Our conservative approach to calling *pfhrp2/3* deletions prevents us from detecting low-density infections and thus could underestimate the true prevalence of these strains. These study results differ from our previous DRC *pfhrp2/3* deletion prevalence estimates; this discrepancy could be attributed to spatial heterogeneity in prevalence, incorrect deletion calls due to laboratory artifact, or different approaches used to identify *pfhrp2/3* deletions. However, our finding of no deletions is in line with our more recent study of symptomatic individuals and a similar study of asymptomatic and symptomatic school-aged children that showed no to little evidence of *pfhrp2/3* deletion in the DRC.<sup>11,19</sup> Together, these results support the continued use of HRP2-based RDTs for the diagnosis of malaria in Kinshasa Province, DRC.

## Acknowledgements

The authors thank the study participants and field teams who conducted study visits. They also wish to express their gratitude to the late Prof. Steven Meshnick for mentorship and his role in the longitudinal study upon which this analysis was based. The following reagents were obtained through BEI Resources, NIAID, NIH: Genomic DNA from *P. falciparum* strain 3D7, MRA-102G, contributed by Daniel J. Carucci; *P. falciparum* strain HB3, MRA-155G, contributed by Thomas E. Wellems; *P. falciparum* strain Dd2, MRA-150G, contributed by David Walliker.

114 115 Financial support 116 This study was funded by R01Al132547 to JJJ and RRD, with partial support from R01Al129812 to AKT, 117 R01Al139520 to JAB and a supplement to RF, T32Al070114 to KB, K24Al134990 to JJJ, and an 118 ASTMH/Burroughs-Wellcome Fund award to JBP. 119 120 Disclosures JBP reports research support from Gilead Sciences and non-financial support from Abbott Laboratories, 121 122 outside the scope of this manuscript.

Figure 1. Study sites in Kinshasa Province, DRC

123

124

- Figure 2. Flow diagram for the detection of pfhrp2/3 deletion in 1,267 samples from 649 participants in
- phase two of the longitudinal study (2018-2021) in Kinshasa Province, DRC

**Table 1.** Baseline characteristics of the study population included in this analysis (1,267 samples with ≥ 100 *Plasmodium falciparum* parasites/μL from 649 participants), during enrollment in the Kinshasa longitudinal study.

	N = 649 participants
Age in years, median (IQR)	9 (5-15)
Age strata, n (%)	
< 1 year	15 (2.3)
1-5 years	166 (25.6)
6-10 years	191 (29.5)
11-15 years	119 (18.4)
16-25 years	76 (11.7)
> 25 years	81 (12.5)
Sex, n (%)	· .
Female	317 (48.8)
Male	332 (51.2)
Malaria in previous 6 months, n (%)	, <i>,</i>
No	311 (51.3)
Yes-once	169 (27.9)
Yes-many	126 (20.8)
Slept under bed net previous night, n (%)	,
No	47 (9.8)
Yes	432 (90.2)
Household size, median (IQR)	8 (6-10)
Site of residence, n (%)	,
Bu (rural)	87 (13.4)
Impuru (rural)	123 (19.0)
Pema (rural)	121 (18.6)
Ngamanzo (peri-urban)	108 (16.6)
lye (peri-urban)	60 (9.2)
Kimpoko (peri-urban)	122 (18.8)
Lingwala (urban)	28 (4.3)
Number of samples per participant, median (IQR)	2 (1-3)

135 Co-author contact information: 136 Ruthly François: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 137 ruthly\_francois@med.unc.edu Melchior Mwandagalirwa Kashamuka<sup>2</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic 138 139 of the Congo; mkashamuka@yahoo.com 140 Kristin Banek<sup>1</sup>: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; kristin\_banek@med.unc.edu 141 Joseph A. Bala<sup>2</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo; 142 jalexandrebala@yahoo.fr 143 144 Marthe Nkalani<sup>2</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo; 145 marthenkalani@gmail.com Georges Kihuma<sup>2</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo; 146 147 georgeskihuma@gmail.com 148 Joseph Atibu<sup>2</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo; 149 fejef576@gmail.com 150 Georges E. Mahilu<sup>2</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo; 151 emomahilu@gmail.com Kyaw L. Thwai<sup>1</sup>: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 152 153 thwai@email.unc.edu Ashenafi Assefa<sup>1</sup>: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States; 154 ashenafi assefa@med.unc.edu 155

Jeffrey A. Bailey<sup>3</sup>: Brown University, Providence, RI, United States; jeffrey\_bailey@brown.edu

Rhoel R. Dinglasan<sup>4</sup>: University of Florida, Gainesville, FL, United States; rdinglasan@epi.ufl.edu

Jonathan J. Juliano: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;
jonathan\_juliano@med.unc.edu

Antoinette Tshefu<sup>2\*</sup>: Kinshasa School of Public Health, Kinshasa, Democratic Republic of the Congo;
antotshe@yahoo.com

Jonathan B. Parr: University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;
jonathan\_parr@med.unc.edu

## References

164

185

165 1. Chiodini PL, Bowers K, Jorgensen P, Barnwell JW, Grady KK, Luchavez J, et al. The heat stability of 166 Plasmodium lactate dehydrogenase-based and histidine-rich protein 2-based malaria rapid 167 diagnostic tests. Trans R Soc Trop Med Hyg. 2007;101(4). 168 2. Geneva: World Health Organization. World Malaria Report 2021. Angewandte Chemie 169 International Edition, 6(11), 951–952. 2021. 170 3. Geneva: World Health Organization. Statement by the Malaria Policy Advisory Group on the 171 urgent need to address the high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and 172 beyond. [Internet]. 2021. Available from: https://www.who.int/news/item/28-05-2021-173 statement-by-the-malaria-policy-advisory-group-on-the-urgent-need-to-address-the-high-174 prevalence-of-pfhrp2-3-gene-deletions-in-the-horn-of-africa-and-beyond 175 Berhane A, Anderson K, Mihreteab S, Gresty K, Rogier E, Mohamed S, et al. Major threat to 4. 176 malaria control programs by plasmodium falciparum lacking histidine-rich protein 2, Eritrea. 177 Emerg Infect Dis. 2018;24(3). 178 5. Feleke SM, Reichert EN, Mohammed H, Brhane BG, Mekete K, Mamo H, et al. Plasmodium 179 falciparum is evolving to escape malaria rapid diagnostic tests in Ethiopia. Nat Microbiol. 180 2021;6(10). 181 Alemayehu GS, Blackburn K, Lopez K, Cambel Dieng C, Lo E, Janies D, et al. Detection of high 6. 182 prevalence of Plasmodium falciparum histidine-rich protein 2/3 gene deletions in Assosa zone, 183 Ethiopia: implication for malaria diagnosis. Malar J. 2021;20(1). 184 Iriart X, Menard S, Chauvin P, Mohamed HS, Charpentier E, Mohamed MA, et al. Misdiagnosis of 7.

imported falciparum malaria from African areas due to an increased prevalence of pfhrp2/pfhrp3







